Maximizing Current Therapies and Exploring Future Directions as PARP Inhibitors Take the Stage in Prostate CancerExpert Perspectives
This curriculum features expert commentaries and case discussions that synthesize data around PARP inhibition and its evolving place in the treatment of patients with prostate cancer. Faculty provide practical guidance to apply available and emerging data in real-world decision-making that clinicians are faced with on a daily basis including: interpreting results to inform treatment decisions, biomarker testing, patient selection, and combination therapy. Video modules are also available as downloadable audio podcasts and transcripts.
Faculty: Neeraj Agarwal, MD; Celestia Higano, MD, FACP; Daniel Petrylak, MD; Patrick G. Pilié, MD; Neal Shore, MD, FACS
Expiration Date: July 08, 2022
CME/CE is no longer available for this activity